AM694

AM694 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2). It was first synthesized in the early 1990s by the laboratory of Roger Pertwee. Research indicates that AM694 has a high affinity for both CB1 and CB2 receptors, with reported binding affinities in the low nanomolar range.

The pharmacological profile of AM694 has been investigated in various in vitro and in vivo studies. In vitro, it has been used to characterize the function of cannabinoid receptors. In vivo, it has been employed in animal models to study the effects of cannabinoid receptor activation on processes such as pain perception, appetite, and motor coordination. AM694 has been noted for its efficacy in preclinical models of inflammatory pain.

Due to its potent activity at cannabinoid receptors, AM694 has been of interest in scientific research exploring the endocannabinoid system. However, it is not approved for medical use in humans. As with many synthetic cannabinoids, its potent effects raise concerns about potential misuse and adverse reactions. Therefore, its use is generally restricted to controlled laboratory settings for scientific investigation.